ClinicalTrials.gg
RecruitingNCT06575465EFIT-BEDUpdated Jan 28, 2025

Evaluating Family & Community-Based Interventions to Improve Treatment Adherence in Metabolic Health Among Negev Bedouins (EFIT-BED)

An interventional study of Healthy lifestyle nutrition, culture and physical activity workshops and Usual care in Community-Based Participatory Research, sponsored by Ariel University. Recruiting at 1 site in Israel. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-28.

Sponsored by Ariel University · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Sep 2024; still recruiting 2 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
170
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 223 studies in Diabetes Mellitus, Type 2 with a site in Israel — 10 open to participants now, 16 under way, 7 of them phase 3. Diabetes Mellitus, Type 2 · Israel.

Planned enrollment
128th of 197
170 · median 343
Started
2024
with 4 others
No phase
39 of 223
4 open now
Primary completion
2025-12
later than 3 of 15 live
Registered
217th of 223
by date

Among the 223 studies in Diabetes Mellitus, Type 2 with a site in Israel, this one is the 128th largest by planned enrollment of the 197 interventional ones that give a count, is one of 5 that started in 2024, is one of 39 with no phase, reaches primary completion later than 3 of the 15 other live ones, and was the 217th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

10 of the 223 studies in Diabetes Mellitus, Type 2 with a site in Israel are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 223 studies in Diabetes Mellitus, Type 2 with a site in Israel, or all of them as a file.
02

Study summary

Background:

The Bedouin community in the Negev faces high rates of type 2 diabetes, low treatment adherence, and increased disease complications. Transition to urban living and changing dietary patterns have exacerbated these issues. Current interventions often overlook the potential of culturally tailored approaches leveraging kinship ties and community resources. This study seeks to address these gaps by examining the impact of a family-centered intervention program.

Objectives:

Primary: Assess the effect of community intervention on Mediterranean diet adherence.

Secondary: Evaluate changes in fasting glucose, HbA1c, lipid profiles, BMI, physical activity, and quality of life.

Methodology:

Study Design: Controlled community intervention trial with two groups (intervention and control).

Participants: 170 Bedouin adults diagnosed with overweight, obesity, metabolic syndrome, prediabetes, or type 2 diabetes.

Intervention: 10 sessions over 12 months focusing on nutrition, physical activity, and behavioral changes, tailored to cultural norms.

Control: Routine care without added intervention. Outcome Measures: Lab tests (HbA1c, lipid profiles), anthropometric measures, Mediterranean diet adherence, physical activity, quality of life, and social belonging.

Recruitment and Data Collection:

Participants will be recruited via Clalit clinics in Rahat, with the support of local community leaders. Data will be collected through medical records, questionnaires, and physical assessments at baseline, 6, and 12 months.

Data Analysis:

Statistical analysis will be performed using SAS/SPSS, employing ANOVA, Chi-square tests, and regression models for outcome prediction.

Ethical Considerations:

Participants' privacy will be ensured through coded data storage. The study will comply with Helsinki guidelines, and participants can withdraw at any time.

Conclusion:

This study aims to provide culturally tailored interventions to improve health outcomes in the Bedouin community, potentially serving as a model for similar minority groups globally.

Read the detailed description

Research Initiator: Prof. Vered Kaufman-Shriqui, Department of Nutrition Sciences, Ariel University, Ariel. Email: veredks@ariel.ac.il Clalit HMO Principal Investigator: Dr. Muflah Ataika, Rahat Counseling Clinic, Southern District, Clalit Health Services.

Co-Investigators:

  • Dr. Walid El Huzayel, Rahat A Clinic, Southern District, Clalit Health Services.
  • Ms. Malak Oubra Abu Alasal, Regional Diabetes Nurse, Southern District, Clalit Health Services.

External Co-Investigators:

  • Prof. Mona Boaz, Head of the Department of Nutrition Sciences at Ariel University in Samaria.
  • Dr. Maya Maor, Department of Sociology and Anthropology, Ariel University.
  • Dr. Samira Alfayoumi Ziadna, Ashkelon College.

Scientific Background and Rationale for the Study The health status of populations is shaped by social, political, economic, and cultural factors that influence individual behaviors. Social and cultural patterns are especially relevant in the context of diabetes, where lifestyle choices, diet, and physical activity play critical roles (Inoyue, 2012). A comprehensive approach targeting all sectors is essential for effective health promotion. However, despite widespread health initiatives, little is known about their long-term impact and sustainability.

The Bedouin community in the Negev has some of the highest rates of type 2 diabetes in Israel, with 40% of those over 50 affected (internal district data). Despite high disease prevalence, there are low success rates in disease management and high rates of complications. The Bedouin society is experiencing a cultural shift from a semi-nomadic lifestyle to permanent housing, which is altering traditional dietary habits (e.g., home-cooked meals vs. ready-made food). The extent to which these changes contribute to rising obesity and diabetes rates is unclear. Additionally, most research on diabetes in the Bedouin community focuses on adherence to standard interventions without considering how cultural norms could serve as unique coping resources (Maor et al., 2023). Studies on other minority groups suggest that community experiences and worldviews can enhance disease management strategies (Chard, 2017; Duwe, 2016; Sanderson, 2012).

Given the Bedouin society's strong clan ties, strategies involving collective actions (e.g., family-wide physical activities) may boost participation and treatment adherence (Maor et al., 2023). Therefore, tailored health promotion programs are essential for reducing health disparities in this community.

In Israel, despite overall high life expectancy, minority groups-especially those in lower socioeconomic strata-experience significantly shorter life spans. This gap is largely due to higher rates of chronic conditions like obesity and heart disease among Arab populations (Swinburn et al., 2011; ICDC, 2012). A 1999-2000 survey found that obesity rates (BMI > 30) in the Arab sector are notably high (Abdeen et al., 2012). A subsequent study involving 17,044 Arab participants (49% men; average age 39.4) and 16,012 Jewish participants (50% men; average age 40.5) confirmed significantly higher BMI and other risk factors (e.g., HDL-C, triglycerides, SBP) in the Arab population (Abdeen et al., 2012; Kalter-Leibovici et al., 2012).

The prevalence of type 2 diabetes in the Arab sector is roughly double that of the Jewish sector (Kalter-Leibovici et al., 2012; Abdeen et al., 2012). Adherence to treatment is particularly low among Bedouins, with over 70% of patients non-compliant, leading to severe complications such as kidney failure and blindness (Chard, 2017; Duwe, 2016). This highlights an urgent need to understand how Bedouin patients manage their condition.

Research Objectives General Objective: This study aims to evaluate whether a community-based intervention targeting healthy lifestyle practices within Bedouin clans can improve physical activity, glycemic control, anthropometric measures, and dietary habits in individuals with metabolic syndrome, prediabetes, and type 2 diabetes beyond routine medical care provided by physicians and clinic staff.

Primary Objective:

To examine the effect of the intervention on the Mediterranean diet score among patients with obesity, metabolic syndrome, prediabetes, and type 2 diabetes over a period of up to one year from their entry into the study.

Secondary Objectives: Among people with overweight, obesity, metabolic syndrome, prediabetes, and type 2 diabetes over a period of up to one year, to examine the effect of the community intervention on:

  1. Fasting blood sugar levels (FPG) and glycosylated hemoglobin levels (HBA1c)
  2. Blood lipid profile (LIPID PROFILE)
  3. Anthropometric measures (weight, BODY MASS INDEX (BMI), waist circumference, blood pressure)
  4. Nutritional intake quality
  5. Health habits and physical activity level
  6. Quality of life
  7. Sense of social belonging We aim to examine whether a healthy lifestyle intervention program within the clan in the research group compared to the control group will lead to improvements in these outcome measures.

Number of Participants and Planned Study Centers:

Number of participants in the study: 170 participants Each intervention group requires 70 people (total 140 participants) + 15 participants in each group in case of dropout (total 170 participants). The intervention group will receive a program to promote a healthy lifestyle. The intervention will be given separately to men and women. There will be 10 meetings. The meeting topics are detailed in the research timeline table. The control group will not receive an intervention program.

The sample size was based on the following assumptions: The sample size was calculated to demonstrate a difference of 0.5±1% in HbA1c levels in a two-sided test α=0.05.

Participant Recruitment Method: Patients insured by Clalit Health Services from two selected clans in Rahat, whose elders agreed to participate in the study, from the Southern District, men and women aged 18 and above, will be recruited by the researchers in the study who are the primary treating physicians identifying suitable patients for participation in the study according to inclusion and exclusion criteria. Recruited patients will be referred for further testing and treatment.

Study Design and Methodology:

Study Design: The study is designed as a controlled community intervention trial. Participants will be divided into two groups: an intervention group and a control group. The intervention group will receive a comprehensive community-based intervention program, while the control group will receive routine care. All outcome measures will be measured at baseline, 6 months from baseline and 12 months from baseline.

Reporting of Adverse Events / Serious Adverse Events:

o At each visit, patients will be questioned about changes in their medical condition and changes in their regular medications. If an adverse event or serious adverse event occurs, it will be reported to the principal investigator and the study initiator according to the requirements of the Helsinki Committee and GCP procedures. The principal investigator will complete an Adverse Event or Serious Adverse Event report form as required.

  • The principal investigator will compile data from all participating clinics.
  • Each patient will be assigned a coded number in a sequential order, consisting of the initials of the patient's name and their recruitment order in the study. Identifying details will be omitted.
  • The encrypted data file will be stored on the principal investigator's computer in the office of Dr. Muflah Ataika at the Clalit Health Services district management in Be'er Sheva.
  • Study documents, including informed consent forms, research questionnaires, and other related materials, will be stored in a locked cabinet at the research site with restricted access to the research team only, according to good clinical practice (GCP) procedures.
  • Identifying details will not be transferred to the study initiator outside of Clalit facilities; only coded data will be transferred.

Laboratory Tests and Any Other Relevant Tests to be Conducted During the Study and Follow-Up Period, and Where They Will Be Performed:

  • Laboratory tests will not be specifically conducted for the study but will be extracted from the participants' medical records during each clinic visit. Anthropometric measurements will be actively checked at each meeting.

Method of Analyzing and Processing Results:

  • Descriptive and inferential statistical analyses will be performed using SAS and/or SPSS software.
  • For continuous variables, a normal distribution analysis will be conducted and, if necessary, a logarithmic transformation.
  • Comparisons between continuous variables will be performed using appropriate statistical tests such as ANOVA (general comparison, and if necessary, between all groups and between each pair of groups).
  • Comparisons of categorical variables will be performed using the Chi-square test and, if possible, the Fisher Exact test.
  • For continuous outcome variables, a multivariate prediction model will be built, including demographic background factors of the participants and the intervention group they were part of.
  • Multivariate comparisons will be conducted using logistic regression or multivariate linear regression as appropriate.

Role of the Sub-Investigators in the Study:

The sub-investigators will oversee all stages of the study implementation and intervention, including training research assistants on research questionnaires and medical teams (dietitians and physiotherapists) to integrate the intervention among the population. Additionally, they will supervise data collection, oversee the work of research assistants, conduct statistical analyses (on de-identified data), and write the research findings.

  1. Ethical Issues of the Trial
  • All subjects will sign an informed consent form prior to inclusion in the study.

    • Pregnant women, special populations, individuals lacking judgment capacity, and children will not be recruited for the study.
  • Participants can withdraw from the study at any time.
  • Number of centers in the study: This study involves one center, the primary investigator's clinic.
03

Conditions studied

  • Community-Based Participatory Research

Keywords

  • Type 2 Diabetes Mellitus
  • Obesity
  • Community based participatory research
  • Health promotion
  • Clinical trial
  • Prediabetes
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Bedouin men and women aged 18 and above
  • Diagnosed with overweight, obesity, metabolic syndrome, prediabetes, or type 2 diabetes
  • Consent to participate in the study

Exclusion criteria

Exclusion Criteria:

  • Individuals with other chronic diseases that might interfere with the study
  • Pregnant or lactating women
  • Individuals unable to provide
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
170 participants (estimated)

Study arms

  • Experimental
    Full Intervention

    * Will receive a tailored healthy lifestyle intervention program focusing on nutrition, physical activity, and behavioral changes. * Ten sessions will be conducted separately for men and women. * Each session will last for approximately 2 hours. * The program will include educational workshops, cooking demonstrations, physical activity sessions, and group discussions.

    Behavioral: Healthy lifestyle nutrition, culture and physical activity workshops

  • Active comparator
    Control group

    Participants will continue to receive standard care from their healthcare providers without additional intervention.

    Other: Usual care

Interventions

  • BehavioralHealthy lifestyle nutrition, culture and physical activity workshops

    The intervention will include monthly sessions in the community setting of physical activity. In addition, monthly nutrition and culture sessions will be held.

  • OtherUsual care

    Usual care patients receive in their primary health care

06

What researchers measure

Primary outcomes

  1. To examine the effect of the intervention on the Mediterranean diet score among patients with obesity, metabolic syndrome, prediabetes, and type 2 diabetes over a period of up to one year from their entry into the study

    Examine changes in Mediterranean score using the Mediterranean diet questionnaire (I-MEDAS), the score ranges from 0-17, with a higher value indicating better adherence to the Mediterranean diet pattern.

    Time frame: Will be examined three times during one year

Secondary outcomes

  1. Fasting blood sugar levels (FPG)

    Level of fasting glucose

    Time frame: Three times during a year

  2. Levels of glycosylated hemoglobin levels (HBA1c)

    Level of HBA1C

    Time frame: Three times during a year

  3. Blood lipid profile (LIPID PROFILE)

    Outcomes of a full lipid profile

    Time frame: Three times a year

  4. Anthropometric measures (weight)

    Weight will be measured in kilograms.

    Time frame: Three times during a year

  5. Anthropometric measures (waist circumference)

    Waist circumference will be measured in centimeters.

    Time frame: Three times during a year

  6. Anthropometric measures (height)

    Height will be measured in meters.

    Time frame: Three times during a year

  7. Body mass index, (BMI)

    Weight and height will be combined to report BMI in kg/m\^2

    Time frame: Three times during a year

  8. Blood pressure

    Systolic and diastolic blood pressure in mm/Hg

    Time frame: Three times during a year

  9. Health habits and physical activity level

    Assessed using a health and physical activity habits questionnaire. Smoking habits will be self reported.

    Time frame: Three times during a year

  10. Reported quality of life

    Evaluated using the European Quality of life-5 Dimension (EQ-5D-5L) questionnaire measures health related quality of life. EQ-5D-5L index scores range from -0.59 to 1, where 1 is the best possible health state

    Time frame: Three times during a year

  11. Sense of belonging

    Assessed using a social and community belonging questionnaire. The score ranges from 10-30, higher score indicates higher sense of belonging.

    Time frame: Three times during a year

07

Study locations

1 of 1 sites recruiting
  • Clalit healthcare clinic
    Rahat, Israel
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Dec 2025, 15 months after the start.

Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 15 months is below that.

Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2024
First posted
Aug 28, 2024
StartActual
Sep 1, 2024
Primary completionEst.
Dec 31, 2025
CompletionEst.
May 31, 2026
Last update
Jan 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06575465
Lead sponsor
Ariel University
Collaborators
Clalit Health Services
Responsible party
Vered Kaufman Shriqui (Associate Professor, Ariel University) — Principal investigator
First posted
Aug 28, 2024
Start date
Sep 1, 2024
Primary completion
Dec 31, 2025 (estimated)
Completion
May 31, 2026 (estimated)
Last update
Jan 28, 2025

Study contacts

Vered Kaufman-Shriqui, PhD
Contact
veredks@ariel.ac.il
+972587751199
Maya Maor, PhD
Contact
mayam@ariel.ac.il
+972526561087
Muflah Ataika, MD
principal investigator · Rahat Counseling Clinic, Southern District, Clalit Health Services.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion